市场调查报告书

血友病稀少因素市场 - 成长,趋势,预测

Rare Hemophilia Factors Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品编码 921266
出版日期 内容资讯 英文 111 Pages
商品交期: 2-3个工作天内
价格
血友病稀少因素市场 - 成长,趋势,预测 Rare Hemophilia Factors Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年01月01日内容资讯: 英文 111 Pages
简介

本报告提供血友病稀少因素的世界市场调查,市场概要,各类型,各地区的市场趋势,市场规模的变化与预测,市场促进、阻碍因素以及市场机会分析,竞争情形,主要企业的简介等全面性资讯。

目录

第1章 简介

  • 调查成果
  • 调查的前提条件
  • 调查范围

第2章 调查手法

第3章 摘要整理

第4章 市场动态

  • 市场概要
  • 成长要素
  • 阻碍因素
  • 波特的五力分析
    • 新加入厂商的威胁
    • 消费者谈判力
    • 供应商谈判力
    • 替代产品的威胁
    • 产业内的竞争

第5章 市场区隔

  • 各治疗
    • 因子浓缩
    • 新鲜冻结血浆(FFP)
    • 低温沉淀
    • 其他
  • 各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 中东、非洲
    • 南美

第6章 竞争情形

  • 企业简介
    • Baxter Healthcare
    • Bayer Healthcare
    • Bio Products Laboratory Ltd.
    • Biogen
    • CSL Behring
    • Novo Nordisk
    • Pfizer, Inc.
    • Takeda Pharmaceutical Co. Ltd.

第7章 市场机会及未来趋势

目录
Product Code: 67120

Market Overview

Certain factors that are driving the market growth include rising adoption and approval of new treatment techniques, a growing number of government initiatives and funding.

The worldwide incidence of hemophilia is not well known but estimated at more than 400,000 people. Approximately 75% of people with hemophilia around the world still receive inadequate treatment or have no access to treatment. Scientists report that hemophilia is three times more prevalent in men worldwide than previously thought and still associated with a poorer life expectancy, especially in low-income countries. Findings of the study, "Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries," were published in the Annals of Internal Medicine. This observational study came in response to a call by the World Federation of Hemophilia to more accurately measure the disease's prevalence and its impact on life expectancy.

Scope of the Report

Hemophilia is a genetic bleeding disorder that prevents the blood from clotting normally. The primary symptom is uncontrolled, often spontaneous bleeding in different areas of the body. The deficiency of fibrinogen, prothrombin, factor V (FV), FVII, FVIII, FIX, FX, FXI, and FXIII, called rare coagulation disorders (RCDs), may result in coagulopathies leading to spontaneous or posttrauma and postsurgery hemorrhages.

Key Market Trends

Fresh frozen plasma (FFP) is Expected to Hold Significant Market Share in the Treatment Segment

Plasma transfusion is indicated for the management of bleeding or to prevent bleeding prior to an urgent invasive procedure in patients requiring replacement of multiple coagulation factors. Fresh frozen plasma is the fluid portion of a unit of whole blood that is frozen in a designated time frame, usually within 8 hours. FFP contains all coagulation factors except platelets. FFP contains fibrinogen (400 to 900 mg/unit), albumin, protein C, protein S, antithrombin, tissue factor pathway inhibitor. FFP can only be administered intravenously. FFP must be ABO compatible with the recipient's red cells. The FFP container and fluid upon visual inspection should have no leakage, clots, or abnormal color.

North America Dominates the Market and Expected to do Same in the Forecast Period

According to the Center for Disease Control and Prevention (CDC), Hemophilia A occurs in 1 in 5,000 live male births. Hemophilia A is about four times as common as hemophilia B. The number of people with hemophilia in the United States is estimated to be about 20,000 individuals (National Hemophilia Foundation, 2018). In the United States, most people with hemophilia are diagnosed at a very young age. Based on CDC data, the median age at diagnosis is 36 months for people with mild hemophilia, 8 months for those with moderate hemophilia, and 1 month for those with severe hemophilia. In about two-thirds of cases, there is a family history of hemophilia. The diagnosis of hemophilia is made using a special blood test and most babies can be tested soon after birth. Sometimes prenatal genetic testing is done to diagnose hemophilia before birth (CDC, 2019).

Competitive Landscape

The global Rare Hemophilia Factors market is moderately competitive and consists of a number of major players. Companies like Baxter Healthcare, Bayer Healthcare, Bio Products Laboratory Ltd., Biogen, CSL Behring, Novo Nordisk, Pfizer, Inc., Takeda Pharmaceutical Co. Ltd., among others, hold the substantial market share in the Rare Hemophilia Factors market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Adoption and Approval of New Treatment Techniques
    • 4.2.2 Growing Number of Government Initiatives and Funding
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Treatment
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Treatment
    • 5.1.1 Factor Concentrate
    • 5.1.2 Fresh frozen plasma (FFP)
    • 5.1.3 Cryoprecipitate
    • 5.1.4 Others
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle East and Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle East and Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Baxter Healthcare
    • 6.1.2 Bayer Healthcare
    • 6.1.3 Bio Products Laboratory Ltd.
    • 6.1.4 Biogen
    • 6.1.5 CSL Behring
    • 6.1.6 Novo Nordisk
    • 6.1.7 Pfizer, Inc.
    • 6.1.8 Takeda Pharmaceutical Co. Ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS